ʻO BEIJING SUCCEEDER TECHNOLOGY INC.

Ua hoʻokuʻu ʻia ka palapala ʻaelike koʻikoʻi ʻehā, i alakaʻi ʻia e ke Kōmike Thrombosis a me Hemostasis o ka Hui Kina o nā Halemai Noiʻi.

Ua hoʻomohala like ʻia ka "Expert Consensus on Clinical Monitoring of Heparin-like Drugs" e ke Kōmike Thrombosis and Hemostasis o ka Hui Kina o nā Halemai Noiʻi a me ka Lālā ʻEpekema Laboratory o ka Chinese Geriatrics Society. ʻO kēia palapala, i kākau pū ʻia e nā loea multidisciplinary mai Kina a puni, ua hala ʻelua mau makahiki e hoʻomohala ai, ma hope o nā kūkākūkā he nui a me nā hoʻoponopono hou ʻana. Ua ʻae hope ʻia ka palapala hope loa a paʻi ʻia i ʻAukake 2025 ma ka Chinese Journal of Laboratory Medicine, Volume 48, Issue 8.

Hāʻawi kēia ʻaelike i ke alakaʻi maʻamau no ka nānā ʻana i nā lāʻau lapaʻau e like me ka heparin, e hāʻawi ana i ke kākoʻo hale hana hilinaʻi no ka hoʻokō palekana a me ka pono o ka lāʻau anticoagulant lapaʻau. I ka hopena, e pōmaikaʻi ia i nā ʻano maʻi like ʻole a e ʻoi aku ka maʻamau a me ka pololei o ka lāʻau heparin anticoagulant.

ʻŌLELO AʻOAʻO

ʻO nā lāʻau lapaʻau e like me Heparin he mau anticoagulants i hoʻohana pinepine ʻia no ka pale ʻana a me ka mālama ʻana i nā maʻi thromboembolic. ʻO ka hoʻohana pono ʻana a me ka nānā pono ʻana i kēia mau lāʻau lapaʻau he mea nui ia no ka hōʻoia ʻana i ka palekana a me ka pono o ka lāʻau lapaʻau. Hoʻopili kēia ʻaelike loea i nā palapala kūloko a me ka honua, e noʻonoʻo pono ana i ke kūlana o kēia manawa a me ka holomua o ka hoʻohana ʻana i ka heparin. Ua hoʻākoakoa ʻo ia i kahi panela o nā loea ma ke kahua antithrombotic, me nā loea hoʻokolohua a me nā loea lapaʻau, e kūkākūkā i nā hōʻailona, ​​​​ka nui, a me ka nānā ʻana i ka heparin. Ma ke ʻano kūikawā, ua wehewehe ʻo ia i ka hoʻopili lapaʻau o nā ʻōkuhi hoʻokolohua e like me ka hana anti-Xa a ua hoʻokumu i nā ʻōlelo aʻoaʻo loea me ka pahuhopu o ka hoʻolaha ʻana i ka hoʻohana palekana a me ka pono o ka heparin a me ka hoʻohālikelike ʻana i ka nānā ʻana i ka hoʻokolohua.He paʻi hou kēia ʻatikala mai: Thrombosis and Hemostasis (CSTH).

Ua komo nui ʻo Beijing Succeeder Technology Inc. (code stock: 688338) i ke kahua o ka ʻike ʻana i ka coagulation mai kona hoʻokumu ʻia ʻana i ka makahiki 2003, a ua kūpaʻa ʻo ia e lilo i alakaʻi ma kēia kahua. Me ke keʻena nui ma Beijing, he hui R&D, hana a kūʻai aku ikaika ka hui, e kālele ana i ka hana hou a me ka hoʻohana ʻana i ka ʻenehana ʻike thrombosis a me hemostasis.

Me kona ikaika loea koʻikoʻi, ua lanakila ʻo Succeeder i 45 mau palapala sila i ʻae ʻia, me 14 mau palapala sila i hana ʻia, 16 mau palapala sila hoʻohālike pono a me 15 mau palapala sila hoʻolālā. Loaʻa i ka hui he 32 mau palapala hoʻopaʻa inoa huahana lāʻau lapaʻau Papa II, 3 mau palapala hoʻopaʻa inoa Papa I, a me ka palapala hōʻoia EU CE no 14 mau huahana, a ua hala i ka palapala hōʻoia ʻōnaehana hoʻokele maikaʻi ISO 13485 e hōʻoia i ka maikaʻi a me ke kūpaʻa o ka maikaʻi o ka huahana.

ʻAʻole wale ʻo Succeeder kahi ʻoihana koʻikoʻi o ka Beijing Biomedicine Industry Leapfrog Development Project (G20), akā ua pae maikaʻi ʻo ia ma ka Science and Technology Innovation Board i ka makahiki 2020, e hoʻokō ana i ka hoʻomohala leapfrog o ka ʻoihana. I kēia manawa, ua kūkulu ka ʻoihana i kahi pūnaewele kūʻai aku ma ka ʻāina holoʻokoʻa e uhi ana i nā haneli o nā ʻelele a me nā keʻena. Kūʻai maikaʻi ʻia kāna huahana ma ka hapa nui o ka ʻāina. Ke hoʻonui nei hoʻi i nā mākeke ma waho a ke hoʻomaikaʻi mau nei i kona hoʻokūkū honua.